Conference call scheduled for 4:30 p.m. ET todayEnd-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLDPositive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductions in Very Long-Chain Fatty Acids and Plasma LipidsStrong Quarter-End Cash Position of $930 MillionSAN DIEGO, Oct. 23, 2 ...

Viking Therapeutics Inc. VKTX is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost 240% year-to-date, largely due to excitement surrounding its weight-loss drug candidate, VK2735.As a new contender in the burgeoning obesity drug market, Viking is not just riding the coattails of industry giants but actively challenging them.Weight-Loss Drug ShowdownViking's VK2735 mimics both GLP-1 and GIP hormones, ai ...

Viking Therapeutics (VKTX) is set to report third-quarter earnings on Oct. 23, after market close. Since the company lacks a marketed drug in its portfolio, we do not expect it to record revenues. The Zacks Consensus Estimate for earnings is pegged at a loss of 24 cents per share.Estimates for 2024 loss per share have risen slightly from 99 cents to $1.00 in the past 60 days. Over the same timeframe, loss per share estimates for 2025 have narrowed from $1.48 to $1.46. Image Source: Zacks Investment Research ...

Shares of Viking Therapeutics (VKTX) have risen 29% in the past three months, significantly outperforming the industry's 2.5% growth. The stock has outperformed the sector and the S&P 500 during the same period. VKTX's shares are also trading above the 50-day and 200-day moving averages. VKTX Stock Outperforms Industry, Sector & S&P 500 Zacks Investment Research Image Source: This uptick in stock price was triggered by positive updates from Viking's pipeline programs. Last week, VKTX reported positive resul ...

Viking recently announced the results of an early-stage clinical trial for VK0214. Shares of pharmaceutical upstart Viking Therapeutics (VKTX 0.72%) have been soaring this year thanks to high hopes for VK2735, its promising GLP-1 weight loss treatment. Although the company doesn't have an approved product yet and isn't generating consistent revenue, the excitement around GLP-1 has been sufficient to send the stock's valuation north of $7 billion. Viking, however, is involved in more than just GLP-1 developm ...

Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2024 after the market close on Wednesday, October 23, 2024. The company will host a conference call to discuss financial resul ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sellside) analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about Viking Therapeutics, Inc. (VKTX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Viking Therapeutics curr ...

We could be witnessing the birth of a major player in the biotech industry. Five years ago, Viking Therapeutics (VKTX 5.43%) was an unknown, clinical-stage biotech. It hardly stood out in a sea of small drugmakers, and most of those never end up producing the kinds of results or performances investors want to see. However, a lot has changed since: Viking still has no products on the market, but its leading candidates have made exciting clinical progress. That's why its shares soared this year. There is stil ...

This company is operating in one of today's hottest markets. Investing in biotech stocks is a fantastic way to grow your money over time. This is because in the early days of these companies' growth stories, their stock prices often remain accessible -- and if their research is successful and produces one or more important products, share prices could explode higher. So it's very possible to get in on a promising biotech stock for $100 or less, hold on for the long term, and watch the value of your investme ...

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $62.45, marking a -0.3% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.21%. Meanwhile, the Dow experienced a drop of 0.14%, and the technology-dominated Nasdaq saw a decrease of 0.05%. Shares of the company have appreciated by 2.98% over the course of the past month, outperforming the Medical sector's loss of 3.28% and lagging the S&P 500's gain of 5.94%. Market participants will be close ...